A5018555892- Epilepsy research and treatment
- Pharmacological Effects and Toxicity Studies
- Genetics and Neurodevelopmental Disorders
- Autism Spectrum Disorder Research
- Neuroscience and Neuropharmacology Research
- Obsessive-Compulsive Spectrum Disorders
- Birth, Development, and Health
- Circadian rhythm and melatonin
- Cardiac electrophysiology and arrhythmias
- Maternal Mental Health During Pregnancy and Postpartum
- Drug Transport and Resistance Mechanisms
- Bipolar Disorder and Treatment
- Genomics and Rare Diseases
- Schizophrenia research and treatment
- Ion Transport and Channel Regulation
- Infectious Encephalopathies and Encephalitis
- Growth Hormone and Insulin-like Growth Factors
- Sleep and Wakefulness Research
- Neuroendocrine Tumor Research Advances
- Neonatal and fetal brain pathology
- Genetic Neurodegenerative Diseases
- Psychosomatic Disorders and Their Treatments
- Ion channel regulation and function
- Pregnancy and Medication Impact
- Antibiotics Pharmacokinetics and Efficacy
East London NHS Foundation Trust
2020-2025
University College London
2021
Bedford Hospital
2019
To characterize the experience of people with epilepsy and aligned healthcare workers (HCWs) during first 18 months COVID-19 pandemic compare experiences in high-income countries (HICs) non-HICs.
Lennox-Gastaut syndrome (LGS) is a severe childhood-onset developmental and epileptic encephalopathy characterized by treatment-refractory seizures, including tonic/atonic 'drop' intellectual impairment slow spike-wave discharges on the electroencephalogram. Fenfluramine, previously prescribed as weight-loss drug but then withdrawn, has recently been approved in US, EU, UK for adjunct treatment of seizures associated with LGS.